A method for determining analytes includes lysing the red blood cells of a whole blood sample, oxidizing the free hemoglobin in the lysed sample, and cleaving FVH from the hemoglobin A1C to form an electrochemical test solution. In one aspect, a first portion of the electrochemical test solution is reacted with fructosyl peptide oxidase and a reduced ruthenium mediator to form a first reaction product. A first electrical property of the first reaction product is measured, the measurement being indicative of hemoglobin A1C in the blood sample. In another aspect, a second portion of the electrochemical test solution is reacted with ferrocyanide to form a second reaction product. A second electrical property of the second reaction product is measured, the measurement being indicative of total hemoglobin in the blood sample. Hemoglobin A1C, total hemoglobin, and % HbA1C are determined based on the first and second electrical properties.

The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.

Provided herein is a method of at least partly removing a biological deposit, such as a dag, from the skin of an animal. The method includes administering to the biological deposit an effective amount of a composition containing a keratinase, and optionally one or both of a reducing agent and a surfactant. Also provided is a composition for use in the aforementioned method as well as a method of making same.

Provided herein is a method of at least partly removing a biological deposit, such as a dag, from the skin of an animal. The method includes administering to the biological deposit an effective amount of a composition containing a keratinase, and optionally one or both of a reducing agent and a surfactant. Also provided is a composition for use in the aforementioned method as well as a method of making same.

Disclosed herein include methods, compositions, and kits suitable for use in detecting the activation level of a signal transducer. In some embodiments, there are provided synthetic protein circuits wherein recruitment of synthetic protein circuit components to an association location upon activation of a signal transducer generates an active effector protein. The effector protein can be configured to carry out a variety of functions when in an active state, such as, for example, inducing cell death. Methods of treating a disease or disorder characterized by aberrant signaling are provided in some embodiments.

Disclosed herein include methods, compositions, and kits suitable for use in detecting the activation level of a signal transducer. In some embodiments, there are provided synthetic protein circuits wherein recruitment of synthetic protein circuit components to an association location upon activation of a signal transducer generates an active effector protein. The effector protein can be configured to carry out a variety of functions when in an active state, such as, for example, inducing cell death. Methods of treating a disease or disorder characterized by aberrant signaling are provided in some embodiments.

The present disclosure relates to proteases having an amino acid sequence with at least 70% sequence identity to the amino acid sequence given in SEQ ID No. 1, across its whole length, and comprising an amino acid substitution on at least one of the positions P9, Q10, Q62, L82, P86, N130, T141, N187, S236 or T253, relating in each case to the numbering according to SEQ ID No. 1. The present disclosure also relates to the production and use thereof. Said type of proteases have a very good cleaning performance.

The present disclosure relates to proteases having an amino acid sequence with at least 70% sequence identity to the amino acid sequence given in SEQ ID No. 1, across its whole length, and comprising an amino acid substitution on at least one of the positions P9, Q10, Q62, L82, P86, N130, T141, N187, S236 or T253, relating in each case to the numbering according to SEQ ID No. 1. The present disclosure also relates to the production and use thereof. Said type of proteases have a very good cleaning performance.

The subject invention pertains to a chimeric antigen receptor, a T cell comprising said CAR and methods of making and using said CAR and said T cell for the treatment of a cancer and/or an immune disease. In specific embodiments, the method comprises the use of T cells comprising CARs to target different antigens on target cells. In further specific embodiments, the CARs of the invention comprise NS3 protease domains and cleavage sites, which NS3 domains are inhibited by small molecule inhibitors for customized CAR-T cell therapy.

The subject invention pertains to a chimeric antigen receptor, a T cell comprising said CAR and methods of making and using said CAR and said T cell for the treatment of a cancer and/or an immune disease. In specific embodiments, the method comprises the use of T cells comprising CARs to target different antigens on target cells. In further specific embodiments, the CARs of the invention comprise NS3 protease domains and cleavage sites, which NS3 domains are inhibited by small molecule inhibitors for customized CAR-T cell therapy.